title: Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
authors.affiliation: Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: Ari
authors.initials: A
authors.lastname: Zimran
authors.forename: Gheona
authors.initials: G
authors.lastname: Altarescu
authors.forename: Mici
authors.initials: M
authors.lastname: Philips
authors.forename: Drorit
authors.initials: D
authors.lastname: Attias
authors.forename: Marina
authors.initials: M
authors.lastname: Jmoudiak
authors.forename: Maher
authors.initials: M
authors.lastname: Deeb
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.forename: Kiran
authors.initials: K
authors.lastname: Bhirangi
authors.forename: Gabriel M
authors.initials: GM
authors.lastname: Cohn
authors.forename: Deborah
authors.initials: D
authors.lastname: Elstein
mesh_terms: D000328:Adult; D000368:Aged; D056947:Enzyme Replacement Therapy; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000473:pathology; D005962:Glucosylceramidase / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D013154:Spleen / Q000473:pathology; D013997:Time Factors
chemical_list: D005962:Glucosylceramidase